<SEC-DOCUMENT>0001213900-21-031157.txt : 20210607
<SEC-HEADER>0001213900-21-031157.hdr.sgml : 20210607
<ACCEPTANCE-DATETIME>20210607091537
ACCESSION NUMBER:		0001213900-21-031157
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210607
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210607
DATE AS OF CHANGE:		20210607

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Citius Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001506251
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				273425913
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38174
		FILM NUMBER:		21998429

	BUSINESS ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016
		BUSINESS PHONE:		(908) 967-6676

	MAIL ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trail One, Inc.
		DATE OF NAME CHANGE:	20110314

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrailOne, Inc.
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea142288-8k_citiuspharma.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CURRENT
REPORT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 13 or 15(d) of</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
Securities Exchange Act of 1934</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Report (Date of earliest event reported) <U>June 7, 2021</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Citius
Pharmaceuticals, Inc.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Nevada</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
or other jurisdiction of incorporation)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%; padding-right: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-206903</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 2%; padding-right: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%; padding-right: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27-3425913</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission
    <BR>
    File Number)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS
    Employer <BR>
    Identification No.)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; width: 49%; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11 Commerce Drive, 1st Floor, Cranford,
    NJ</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; width: 2%; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; width: 49%; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07016</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD STYLE="text-align: center; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant's
telephone number, including area code <U>(908) 967-6677</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&#9744;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt">&#9744;</TD><TD STYLE="padding-left: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
                                            communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt">&#9744;</TD><TD STYLE="padding-left: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
                                            communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities registered pursuant to
Section 12(b) of the Act:</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; padding-right: 0pt; padding-left: 0pt"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</FONT></P></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-right: 0pt; width: 2%; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; padding-right: 0pt; padding-left: 0pt"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol(s)</FONT></P></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-right: 0pt; width: 2%; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; padding-right: 0pt; padding-left: 0pt"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange</FONT></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    which registered</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: center; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock, $0.001 par
    value</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: center; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: center; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CTXR</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: center; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: center; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Nasdaq Capital Market</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: center; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants to purchase common
    stock</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: center; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: center; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CTXRW</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: center; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: center; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Nasdaq Capital Market</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company &#9744;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
8.01 Other Events.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 7, 2021, Citius Pharmaceuticals, Inc. issued a press release announcing that it has been added to the Russell 2000&reg; Index at
the conclusion of the Russell US Indexes annual reconstitution, effective at the opening of the U.S. equity markets on June 28, 2021.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
9.01. Financial Statements and Exhibits.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;<U>Exhibits</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following exhibit is filed herewith:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 91%; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No.</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><A HREF="ea142288ex99-1_citiuspharma.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release dated June 7, 2021.</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CITIUS
    PHARMACEUTICALS, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    &nbsp;June 7, 2021</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Myron Holubiak</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Myron
    Holubiak</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea142288ex99-1_citiuspharma.htm
<DESCRIPTION>PRESS RELEASE DATED JUNE 7, 2021
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<IMG SRC="ex99-1_01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Citius
Pharmaceuticals to be Added to Russell</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>2000<SUP>&reg;
</SUP>Index</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRANFORD,
N.J., June 7, 2021 -- Citius Pharmaceuticals, Inc. (&ldquo;Citius&rdquo; or the &ldquo;Company&rdquo;) (Nasdaq: CTXR), a biopharmaceutical
company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products
in adjunct cancer care, unique prescription products and stem cell therapy, today announced that it is set to be added to the Russell
2000<SUP>&reg;</SUP> Index at the conclusion of the Russell US Indexes annual reconstitution, effective at the opening of the U.S. equity
markets on June 28, 2021.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Our
inclusion in the Russell index is an important milestone for Citius that reflects the continued progress we are making to develop and
commercialize first-in-class&nbsp;treatment options for patients around the world. We welcome the enhanced visibility of our diversified
pipeline and long-term growth potential, and look forward to sharing our future milestones with a broader investment community,&rdquo;
said Myron Holubiak, President and Chief Executive Officer of Citius.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FTSE
Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. Membership
in the small-cap Russell 2000<SUP>&reg;</SUP> Index, which remains in place for one year, is based on membership in the broad-market
Russell <FONT STYLE="font-family: Times New Roman, Times, Serif">3000</FONT><FONT STYLE="font-family: Symbol"><SUP>&Ograve;</SUP></FONT> Index. Citius stock will also be automatically added to the appropriate growth and value indexes.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Russell
indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.
Approximately $9 trillion in assets are benchmarked against Russell&rsquo;s US indexes. Russell indexes are part of FTSE Russell, a leading
global index provider.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information on the Russell 2000<SUP>&reg;</SUP> Index and the Russell indexes reconstitution, visit the FTSE Russell website.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Citius Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Citius
is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products,
with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. The Company&rsquo;s lead
product candidate, Mino-Lok<SUP>&reg;</SUP>, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream
infections (CRBSIs), is currently enrolling patients in a Phase 3 pivotal superiority trial. Mino-Lok&reg; was granted Fast Track designation
by the U.S. Food and Drug Administration (FDA). Through its subsidiary, NoveCite, Inc., Citius is developing a novel proprietary mesenchymal
stem cell treatment derived from induced pluripotent stem cells (iPSCs) for acute respiratory conditions, with a near-term focus on Acute
Respiratory Distress Syndrome (ARDS) associated with COVID-19. For more information, please visit www.citiuspharma.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Safe
Harbor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release may contain &ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future
events impacting Citius. You can identify these statements by the fact that they use words such as &ldquo;will,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;plan,&rdquo; &ldquo;should,&rdquo; and &ldquo;may&rdquo; and other words and terms of similar
meaning or use of future dates. Forward-looking statements are based on management&rsquo;s current expectations and are subject to risks and
uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause
actual results to differ materially from those currently anticipated are: risks relating to becoming included and remaining included
in the Russell 2000 index; our ability to successfully undertake and complete clinical trials and the results from those trials for our
product candidates; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical
testing; the early stage of products under development; the estimated markets for our product candidates and the acceptance thereof by
any market; the ability of our product candidates to impact the quality of life of our target patient populations; our need for substantial
additional funds; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability
to attract, integrate, and retain key personnel; our ability to obtain, perform under and maintain financing and strategic agreements
and relationships; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely
basis; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; government regulation; competition;
as well as other risks described in our SEC filings. These risks have been and may be further impacted by Covid-19. Accordingly, these
forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these
forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission (&ldquo;SEC&rdquo;)
filings which are available on the SEC&rsquo;s website at www.sec.gov, including in our Annual Report on Form 10-K for the year ended
September 30, 2020, filed with the SEC on December 16, 2020 and updated by our subsequent filings with the Securities and Exchange Commission.
These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any
changes in events, conditions or circumstances on which any such statement is based, except as required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Relations for Citius Pharmaceuticals:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew
Scott</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
President, Special Projects</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">T:
908-967-6677 x105</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E:
ascott@citiuspharma.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ilanit
Allen</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
President, Corporate Communications and Investor Relations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">T:
908-967-6677 x113</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E:
iallen@citiuspharma.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  R 2,# 2(  A$! Q$!_\0
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M;BYMTN8XIX)9(&D$J1S1.R!9$+;%S<V]G;W%Y>7$-K:6L,MS=75S+'!;VUO
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MQ%XHGG^*GPPM] DN?%V@:_;6=N;K7K^_AL_[3NS:1WMOYO\ 3S_P0K_X-_\
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M:E\#_BI911W-QOE\J34)/"-EJDDJ^:T:S>)O!H$DFQ&=O2/BI;:A_P %2_\
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M;&$#3=0M_@[X#EU:_6>.8V-XDRSM>21L\W^IE\??VQOV5OV5M7^&^B?M*_M
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MZ9XDT76/#NM6D6H:-KVEZAHNK6$Z[H+W3-4M)K&_M)E_BBN;6>6&1>Z.17X
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MM8I=UM)JWB:=_#WA&&YC!PE_I.E:/XDNE5QN%EXH@D&%F&?KC]BC_@C]XO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
7%%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
